SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent.

Slides:

Advertisements

Similar presentations

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,

Advertisements

Attenuation of the “White-Coat Effect” by Antihypertensive Treatment and Regression of Target Organ Damage by Gianfranco Parati, Luisa Ulian, Lorena Sampieri,

Dose-escalation patient response.

IDH1 mutant glioma cells are sensitive to TMZ

Clonal evolution of resistance to sequential ALK inhibitor therapy.

Melanoma donor (MD) NK cells are functionally impaired/exhausted.

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)

Improved outcome of treating locally advanced lung cancer with the use of Lattice Radiotherapy (LRT): A case report Beatriz E. Amendola, Naipy C. Perez,

Coiffier B et al. Proc ASH 2010;Abstract 857.

A, baseline and 4-week PET scan from patient 2 (MET c

Histopathologic features (all images at ×10 magnification).

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Metformin decreases mTORC1 activity in the basal layer of oral epithelial dysplasias and mitotic activity in the hyperplastic epithelium. Metformin decreases.

Use of standardized uptake value thresholding for target volume delineation in pediatric Hodgkin lymphoma Amanda J. Walker, MD, Alin Chirindel, MD, Robert.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.

Clinical responses in patients.

Waterfall plots of the best per cent change from baseline in sum of longest diameters (SLD) for target lesions. Waterfall plots of the best per cent change.

Miralem Pasic et al. JCIN 2015;8:1-9

FLAIR scan, FA map, and fiber tracking in a 38-year-old patient with TBI who was imaged 2 weeks after the initial trauma. FLAIR scan, FA map, and fiber.

Nina C. Wunderlich et al. JIMG 2015;8:

Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular.

Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer. Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Inhibition of lung cancer cell proliferation and viability by CYT387.

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Two-staged stent implantation for multiple supra-aortic lesions

The Hippo pathway acts as a modifier of pNF.

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction.

Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases. Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

Targeting HR via CDK inhibition resensitizes recurrent cultures to temozolomide (TMZ). Targeting HR via CDK inhibition resensitizes recurrent cultures.

Duration of treatment and intervals of radiographic and ctDNA response

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

SY-1425 induces maturation in RARA-high AML

Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.

Relationships between number and site of traumatic microbleeds and clinical and imaging parameters. Relationships between number and site of traumatic.

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

Individual treatment outcomes of 20 patients treated with afatinib and 12 patients treated with afatinib and trastuzumab. Individual treatment outcomes.

Change in FES uptake in the tumor during fulvestrant treatment.

Frequent coamplification of RTKs in MET-amplified EGC

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Representative patient responses to ulixertinib.

Genomic determinants of response to cytotoxic chemotherapy.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

Cell lines from hematologic cancers, including multiple myeloma (MM), AML, and DLBCL, exhibit a strong dependency on MCL1 for survival. Cell lines from.

A, left: LNCaP cells were cultured in media containing complete serum, treated for 24 hours with either ethanol control (0.01%), ABT888 (2.5 mmol/L), or.

Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.

Survival, subsequent therapies, and response.

Effect of dexamethasone on PCDGF/GP88 mRNA and protein expressions and effect of PCDGF/GP88 on dexamethasone-induced cell death. Effect of dexamethasone.

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

BME treatment increases cytotoxic activity of NK3

SCLC PDX models recapitulate patient responses to an experimental therapy. SCLC PDX models recapitulate patient responses to an experimental therapy. A,

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Treatment-induced immune cell changes.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

A patient who had sudden onset of aphasia and right paresthesias 5 years earlier and who partially recovered neurologic function after treatment of the.

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

Presentation transcript:

SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. Waterfall plot showing the best overall change in the sum of the product of the diameters (SPD) in all target lesions (A) and distal sites (B) by lymphoma subtype. Patients achieving a partial response (*), complete response (#), or progression (⁁) by the Revised 2007 International Working Group criteria are shown. C, A patient with FL treated in the right inguinal lesion (white arrow, top) has both local and systemic responses (para-aortic lesion; yellow arrow, middle) as seen in the initial pretreatment imaging and 6 months after treatment. A second patient with FL treated in the right cervical lesion (white arrow, bottom) has both local and systemic responses (left cervical lesion; yellow arrow, bottom) as seen in the initial pretreatment imaging and 21 months after treatment. D and E, Spider plot showing change over time in the sum of the product of the diameters in all lesions (D) or just distal sites (E; excluding lesion A) by dose in patients with FL. Matthew J. Frank et al. Cancer Discov 2018;8:1258-1269 ©2018 by American Association for Cancer Research